gnidimacrin and HIV-Infections

gnidimacrin has been researched along with HIV-Infections* in 1 studies

Other Studies

1 other study(ies) available for gnidimacrin and HIV-Infections

ArticleYear
Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β.
    Journal of medicinal chemistry, 2015, Nov-12, Volume: 58, Issue:21

    HIV-1-latency-reversing agents, such as histone deacetylase inhibitors (HDACIs), were ineffective in reducing latent HIV-1 reservoirs ex vivo using CD4 cells from patients as a model. This deficiency poses a challenge to current pharmacological approaches for HIV-1 eradication. The results of this study indicated that gnidimacrin (GM) was able to markedly reduce the latent HIV-1 DNA level and the frequency of latently infected cells in an ex vivo model using patients peripheral blood mononuclear cells. GM induced approximately 10-fold more HIV-1 production than the HDACI SAHA or romidepsin, which may be responsible for the effectiveness of GM in reducing latent HIV-1 levels. GM achieved these effects at low picomolar concentrations by selective activation of protein kinase C βI and βII. Notably, GM was able to reduce the frequency of HIV-1 latently infected cells at concentrations without global T cell activation or stimulating inflammatory cytokine production. GM merits further development as a clinical trial candidate for latent HIV-1 eradication.

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Diterpenes; Enzyme Activation; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Protein Kinase C beta; Virus Latency

2015